A Phase 3 interventional study of Semaglutide and Placebo semaglutide in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 28th largest by enrollment, is one of 19 that started in 2022, is one of 42 in phase 3, and was the 53rd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 19 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 53rd largest by enrollment of the 166 interventional ones that give a count, is one of 13 that started in 2022, is one of 62 in phase 3, and was the 93rd registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 307 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 64 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), and 25 mg (weeks 13 to 64).
Drug: Semaglutide
Participants will receive placebo tablets matched to semaglutide orally once daily for 64 weeks.
Drug: Placebo semaglutide
Semaglutide tablets orally once daily for 64 weeks.
Semaglutide placebo-matching tablets orally once daily for 64 weeks.
Percentage Change in Body Weight
Percentage change in body weight from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.
Time frame: At end of treatment (week 64)
Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)
Number of participants who achieved ≥ 10% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.
Time frame: At end of treatment (week 64)
Number of Participants Who Achieved Body Weight Reduction ≥ 15% (Yes/No)
Number of participants who achieved ≥ 15% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction.
Time frame: At end of treatment (week 64)
Number of Participants Who Achieved Body Weight Reduction ≥ 20% (Yes/No)
Number of participants who achieved ≥ 20% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction.
Time frame: At end of treatment (week 64)
Change in Physical Function Domain (5-items) Score Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT)
Change in physical function domain score IWQOL-Lite-CT from baseline (week 0) to the end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'.
Time frame: Baseline (week 0), end of treatment (week 64)
Number of Participants Who Achieved ≥14.6 IWQOL-Lite-CT Physical Function Domain (PFD) Score (Yes/No)
Number of participants who achieved ≥14.6 in IWQOL-Lite-CT PFD score (Yes/No) from baseline to end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Body Weight - Kilogram (kg)
Change in body weight from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Body Mass Index (BMI)
Change in BMI from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Diastolic Blood Pressure
Change in diastolic blood pressure from randomisation (week 0) to end of treatment (week 64) is presented.
Time frame: Randomisation (week 0), end of treatment (week 64)
Change in Glycosylated Haemoglobin (HbA1c)
Change in HbA1c from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Total Cholesterol - Ratio to Baseline
Change in total cholesterol (measured in millimoles per liter \[mmol/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline
Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline
Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Very Low-Density Lipoproteins (VLDL) Cholesterol - Ratio to Baseline
Change in VLDL cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Triglycerides - Ratio to Baseline
Change in triglycerides (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Free Fatty Acids - Ratio to Baseline
Change in free fatty acids (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline
Change in high sensitivity C-Reactive Protein (hsCRP) (milligram per litre \[mg/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Fasting Plasma Glucose (FPG)
Change in FPG measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
Change in Fasting Serum Insulin - Ratio to Baseline
Change in fasting serum insulin measured in picomoles per liter (pmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
Time frame: Baseline (week 0), end of treatment (week 64)
Number of Participants With Body Mass Index (BMI) Less Than (<) 30 at Week 64 (Yes/no)
Number of participants with BMI \<30 at the end of treatment (week 64) from baseline (week 0) is presented. The outcome measure is applicable for participants with BMI ≥ 30 at baseline (week 0). In the reported data, 'Yes' infers the number of participants who have achieved BMI less than 30, whereas 'No' infers the number of participants who have not achieved BMI less than 30 at week 64.
Time frame: From baseline (week 0) to end of treatment (week 64)
Number of Participants With Change in Glycaemic Status
Number of participants with change in glycaemic status from baseline (week 0) to the end of treatment (week 64) is presented. These categories were set as per the following criteria: 1) Normo-glycaemia: glycated haemoglobin (HbA1c) \<5.7%; 2) Pre-diabetes: 5.7% \<= HbA1c \< 6.5% 3) Type 2 diabetes: HbA1c \>=6.5%.
Time frame: Baseline (week 0), end of treatment (week 64)
Number of Treatment Emergent Adverse Events (TEAEs)
Number of treatment emergent adverse events from baseline (week 0) to end of study (week 71) is presented. An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.
Time frame: From baseline (week 0) to end of study (week 71)
Number of Serious Treatment Emergent Adverse Events
Number of treatment emergent serious adverse events from baseline (week 0) to end of study (week 71) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.
Time frame: From baseline (week 0) to end of study (week 71)
Change in Pulse
Change in pulse from baseline (week 0) to end of treatment (week 64) is presented.
Time frame: Baseline (week 0), end of treatment (week 64)
The trial was conducted at 22 sites in 4 countries (Canada, Germany, Poland, and United States).
| Milestone | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Started | 205 | 102 |
| Full analysis set | 205 | 102 |
| Safety analysis set | 204 | 102 |
| Completed | 196 | 94 |
| Not completed | 9 | 8 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 7 | 7 |
| Withdrew: Physician decision | 1 | 0 |
Percentage change in body weight from baseline (week 0) to end of treatment (week 64) is presented.
| Percentage change in body weight | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Percentage Change in Body Weight | -14.4 ± 10.5 | -2.5 ± 7.9 |
Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Yes | 152 | 28 |
| No | 40 | 62 |
Number of participants who achieved ≥ 10% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Yes | 121 | 13 |
| No | 71 | 77 |
Number of participants who achieved ≥ 15% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Yes | 96 | 5 |
| No | 96 | 85 |
Number of participants who achieved ≥ 20% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Yes | 57 | 3 |
| No | 135 | 87 |
Change in physical function domain score IWQOL-Lite-CT from baseline (week 0) to the end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'.
| Score on a scale | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Physical Function Domain (5-items) Score Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) | 16.8 ± 20.4 | 8.3 ± 16.7 |
Number of participants who achieved ≥14.6 in IWQOL-Lite-CT PFD score (Yes/No) from baseline to end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Yes | 104 | 31 |
| No | 84 | 58 |
Change in body weight from baseline (week 0) to end of treatment (week 64) is presented.
| kg | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Body Weight - Kilogram (kg) | -15.0 ± 11.3 | -2.3 ± 8.2 |
Change in BMI from baseline (week 0) to end of treatment (week 64) is presented.
| Kilogram per square meter (kg/m^2) | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Body Mass Index (BMI) | -5.3 ± 4.0 | -0.9 ± 2.8 |
Change in waist circumference from baseline (week 0) to end of treatment (week 64) is presented.
| centimeter (cm) | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Waist Circumference | -12.9 ± 12.3 | -3.1 ± 11.2 |
Change in systolic blood pressure from baseline (week 0) to end of treatment (week 64) is presented.
| Millimeters of mercury (mmHg) | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -7 ± 15 | -5 ± 15 |
Change in diastolic blood pressure from randomisation (week 0) to end of treatment (week 64) is presented.
| mmHg | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure | -3 ± 9 | -2 ± 10 |
Change in HbA1c from baseline (week 0) to end of treatment (week 64) is presented.
| Percentage of HbA1c | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -0.3 ± 0.3 | -0.0 ± 0.2 |
Change in total cholesterol (measured in millimoles per liter \[mmol/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of total cholesterol | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Total Cholesterol - Ratio to Baseline | 0.96 ± 15.3 | 0.98 ± 16.4 |
Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of HDL | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline | 1.04 ± 15.8 | 0.99 ± 13.7 |
Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of LDL | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline | 0.96 ± 24.0 | 0.99 ± 25.9 |
Change in VLDL cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of VLDL | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Very Low-Density Lipoproteins (VLDL) Cholesterol - Ratio to Baseline | 0.80 ± 38.9 | 0.92 ± 36.8 |
Change in triglycerides (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of triglycerides | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Triglycerides - Ratio to Baseline | 0.80 ± 39.2 | 0.93 ± 36.0 |
Change in free fatty acids (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of free fatty acids | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Free Fatty Acids - Ratio to Baseline | 0.86 ± 64.2 | 0.95 ± 76.6 |
Change in high sensitivity C-Reactive Protein (hsCRP) (milligram per litre \[mg/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of hsCRP | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline | 0.50 ± 111.9 | 0.91 ± 122.8 |
Change in FPG measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 64) is presented.
| mg/dL | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -7.3 ± 10.8 | 0.1 ± 12.0 |
Change in fasting serum insulin measured in picomoles per liter (pmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).
| Ratio of fasting serum insulin | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Fasting Serum Insulin - Ratio to Baseline | 0.74 ± 57.9 | 1.03 ± 62.5 |
Number of participants with BMI \<30 at the end of treatment (week 64) from baseline (week 0) is presented. The outcome measure is applicable for participants with BMI ≥ 30 at baseline (week 0). In the reported data, 'Yes' infers the number of participants who have achieved BMI less than 30, whereas 'No' infers the number of participants who have not achieved BMI less than 30 at week 64.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Yes | 77 | 9 |
| No | 102 | 77 |
Number of participants with change in glycaemic status from baseline (week 0) to the end of treatment (week 64) is presented. These categories were set as per the following criteria: 1) Normo-glycaemia: glycated haemoglobin (HbA1c) \<5.7%; 2) Pre-diabetes: 5.7% \<= HbA1c \< 6.5% 3) Type 2 diabetes: HbA1c \>=6.5%.
| Participants | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Normo-glycaemia (week 0) — Normo-glycaemia (week 64) | 92 | 35 |
| Normo-glycaemia (week 0) — Pre-diabetes (week 64) | 5 | 11 |
| Normo-glycaemia (week 0) — Diabetes (week 64) | 0 | 0 |
| Pre-diabetes (week 0) — Normo-glycaemia (week 64) | 64 | 13 |
| Pre-diabetes (week 0) — Pre-diabetes (week 64) | 25 | 26 |
| Pre-diabetes (week 0) — Diabetes (week 64) | 1 | 0 |
| Diabetes (week 0) — Normo-glycaemia (week 64) | 0 | 0 |
| Diabetes (week 0) — Pre-diabetes (week 64) | 3 | 0 |
| Diabetes (week 0) — Diabetes (week 64) | 0 | 1 |
Number of treatment emergent adverse events from baseline (week 0) to end of study (week 71) is presented. An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.
| Events | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 1239 | 432 |
Number of treatment emergent serious adverse events from baseline (week 0) to end of study (week 71) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.
| Events | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Number of Serious Treatment Emergent Adverse Events | 17 | 13 |
Change in pulse from baseline (week 0) to end of treatment (week 64) is presented.
| Beats per minute (Beats/min) | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Change in Pulse | 2 ± 10 | 1 ± 9 |
Collected over From week 0 to week 71. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Semaglutide 25 mg | 0/205 (0%) | 8/204 (3.9%) | 172/204 (84.3%) |
| Placebo | 0/102 (0%) | 9/102 (8.8%) | 79/102 (77.5%) |
| Event | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/204 | 1/102 |
| Adrenal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/204 | 1/102 |
| Cervical polypReproductive system and breast disorders | 0/204 | 1/102 |
| DepressionPsychiatric disorders | 0/204 | 1/102 |
| Fracture displacementInjury, poisoning and procedural complications | 0/204 | 1/102 |
| FuruncleInfections and infestations | 0/204 | 1/102 |
| HyponatraemiaMetabolism and nutrition disorders | 0/204 | 1/102 |
| HypotensionVascular disorders | 0/204 | 1/102 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/204 | 1/102 |
| Pancreatitis acuteGastrointestinal disorders | 0/204 | 1/102 |
| Event | Oral Semaglutide 25 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 95/204 | 19/102 |
| VomitingGastrointestinal disorders | 63/204 | 6/102 |
| NasopharyngitisInfections and infestations | 43/204 | 27/102 |
| COVID-19Infections and infestations | 41/204 | 18/102 |
| ConstipationGastrointestinal disorders | 41/204 | 10/102 |
| DyspepsiaGastrointestinal disorders | 37/204 | 9/102 |
| DiarrhoeaGastrointestinal disorders | 36/204 | 9/102 |
| HeadacheNervous system disorders | 24/204 | 9/102 |
| EructationGastrointestinal disorders | 21/204 | 2/102 |
| InfluenzaInfections and infestations | 15/204 | 10/102 |
FAS included all randomised participants. Participants were analysed according to the randomised treatment.
| Age, Continuous(Years) | Oral Semaglutide 25 mg | Placebo | Total |
|---|---|---|---|
| Mean | 48 ± 13 | 47 ± 13 | 48 ± 13 |
| Sex: Female, Male(Participants) | Oral Semaglutide 25 mg | Placebo | Total |
|---|---|---|---|
| Female | 155 | 87 | 242 |
| Male | 50 | 15 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Oral Semaglutide 25 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 7 | 24 |
| Not Hispanic or Latino | 188 | 95 | 283 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Oral Semaglutide 25 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Black or African American | 13 | 9 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 190 | 91 | 281 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Ran from Oct 2022 to primary completion in Apr 2024, 18 months.
Results were first posted in Feb 2026, 1 year 10 months after primary completion. A results delay was requested in Apr 2025.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide